Rigel Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Rigel Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- South SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- RIGL
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001034842
- EIN
- 94-3248524
Board of directors
-
Alison L. Hannah · DirectorSince 2023
-
Anthony Gregg Lapointe · DirectorSince 2023
-
Brian L. Kotzin · DirectorSince 2023
-
Gary A. Lyons · DirectorSince 2023
-
Jane Wasman · DirectorSince 2023
-
Kamil Ali-Jackson · DirectorSince 2023
-
Mark W. Frohlich · DirectorSince 2025
-
Michael Patrick Miller · DirectorSince 2026
-
Raul R. Rodriguez · Director · CEO, PresidentSince 2023
-
Walter H. Moos · DirectorSince 2023
Chief executives
Raul R. Rodriguez
· CEO, President
Dates unknown
Director election results
Annual meeting of May 14, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
86.2%
-
97.7%
-
98.2%
Board connections
7 of this board's directors also sit on 9 other boards.
- via Gary A. Lyons
- via Brian L. Kotzin
- via Alison L. Hannah
- via Gary A. Lyons
- via Kamil Ali-Jackson
- via Michael Patrick Miller
- via Jane Wasman
- via Anthony Gregg Lapointe
- via Gary A. Lyons
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $305,865
- 3 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 2, 2026 | Schorno Dean L Officer (EVP & Chief Financial Officer) | Option exercise | +694 | $12.70 | $8,814 |
| Sep 2, 2026 | Schorno Dean L Officer (EVP & Chief Financial Officer) | Option exercise | +620 | $18.70 | $11,594 |
| Sep 2, 2026 | Schorno Dean L Officer (EVP & Chief Financial Officer) | Option exercise | +2,000 | $24.20 | $48,400 |
| Sep 2, 2026 | Schorno Dean L Officer (EVP & Chief Financial Officer) | Option exercise | +1,286 | $24.20 | $31,121 |
| Sep 1, 2026 | Furey Raymond J. Officer (EVP, GC, CCO & Corp Sec) | Shares withheld for tax | −877 | $47.50 | $41,658 |
| Sep 1, 2026 | Raul R. Rodriguez Director, Officer (CEO, President) | Shares withheld for tax | −2,424 | $47.50 | $115,140 |
| Sep 1, 2026 | Santos David A Officer (EVP, Chief Commercial Officer) | Shares withheld for tax | −874 | $47.50 | $41,515 |
| Sep 1, 2026 | Schorno Dean L Officer (EVP & Chief Financial Officer) | Shares withheld for tax | −928 | $47.50 | $44,080 |
| Jul 8, 2026 | Alison L. Hannah Officer (EVP, Chief Medical Officer) | Grant or award | +24,400 | — | — |
| Jun 22, 2026 | Kamil Ali-Jackson Director | Open-market sale | −2,500 | $35.00 | $87,500 |
| Jun 1, 2026 | Schorno Dean L Officer (EVP & Chief Financial Officer) | Option exercise | +1,200 | $18.70 | $22,440 |
| Jun 1, 2026 | Santos David A Officer (EVP, Chief Commercial Officer) | Shares withheld for tax | −874 | $29.86 | $26,098 |
| Jun 1, 2026 | Rojkjaer Lisa Officer (EVP, Chief Medical Officer) | Shares withheld for tax | −850 | $29.86 | $25,381 |
| Jun 1, 2026 | Raul R. Rodriguez Director, Officer (CEO, President) | Shares withheld for tax | −2,424 | $29.86 | $72,381 |
| Jun 1, 2026 | Furey Raymond J. Officer (EVP, GC, CCO & Corp Sec) | Shares withheld for tax | −877 | $29.86 | $26,187 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.